BioSpace News Archive

Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.

Cartesian’s Descartes-08 is a new chimeric antigen receptor (CAR) - T cell therapy that strives to target the myasthenia gravis disease at its source.

Biogen Inc. announced topline results from its pivotal Phase 3 VALOR study of tofersen, an investigational antisense drug being evaluated for people with superoxide dismutase 1 amyotrophic lateral sclerosis.

Ionis Pharmaceuticals, Inc. partner Biogen announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 amyotrophic lateral sclerosis.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that the sintilimab ORIENT-31 study has met its prespecified primary endpoint of progression-free survival at the first interim analysis.